AU696938C - Therapeutic methods and preparations using rubidium ions - Google Patents

Therapeutic methods and preparations using rubidium ions

Info

Publication number
AU696938C
AU696938C AU46149/96A AU4614996A AU696938C AU 696938 C AU696938 C AU 696938C AU 46149/96 A AU46149/96 A AU 46149/96A AU 4614996 A AU4614996 A AU 4614996A AU 696938 C AU696938 C AU 696938C
Authority
AU
Australia
Prior art keywords
rubidium
preparation
rubidium chloride
patient
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU46149/96A
Other versions
AU4614996A (en
AU696938B2 (en
Inventor
John Lai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN1048A external-priority patent/AUPN104895A0/en
Application filed by Individual filed Critical Individual
Priority to AU46149/96A priority Critical patent/AU696938C/en
Publication of AU4614996A publication Critical patent/AU4614996A/en
Application granted granted Critical
Publication of AU696938B2 publication Critical patent/AU696938B2/en
Publication of AU696938C publication Critical patent/AU696938C/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Description

THERAPEUTIC METHODS AND PREPARATIONS USING RUBIDIUM IONS
Field of the Invention
This invention relates to the treatment of a variety of distressing disorders that occur in both man and animals and to compositions and preparations for use in such treatment. As used herein, the term "patient" includes within its scope both humans and animals.
The invention finds particular application in the treatment of many seemingly unrelated complaints that cause huge health losses to individuals and huge financial losses to society. Some important applications of the present invention which have been noted to date include:
1) Relief of the pain in an extremely wide range of painful musculoskeletal and neural disorders.
2) The suppressing or relief of pain associated with respiratory disorders, such as of coughs as well as most of the symptoms of hayfever. This includes such important afflictions as asthma and the common cold, and croup attack in children. Background of the Invention
The current conventional Western medical practice for management of arthritis and other soft tissue injuries includes the administration of steroids and non-steroidal anti-inflammatory drugs by topical application, orally or by injection into the affected areas of the patient.
Steroids, such as the corticosteroids, often have undesirable side effects such as the promotion of peptic ulcers, increased susceptibility to infection, mental irritability, nervousness, obesity, muscular weakness, osteoporosis, diabetes, and adrenal insufficiency which, in some cases, may cause the patient to collapse.
Non-steroidal anti-inflammatory drugs generally have a less debilitating effect on patients. However, they are not without side effects. Stomach disorders, gastric pain, diarrhoea, dizziness or light headiness, stomach or duodenal ulcers and long term blood loss have all been reported in patients treated with non-steroidal anti-inflammatory drugs. Where the anti-inflammatory drugs have been administered topically, furth difficulties such as skin irritation, odor and staining may also be experienced.
Most commercially available topical preparations for the treatment musculoskeletal disorders contain methyl salicylate as the active ingredient, b methyl salicylate is a toxic drug which can be lethal in large doses and it is possib that such large lethal doses may be attained by absorption through the skin.
The administration of gold has also been promoted in the management arthritis. However, side effects have been reported in patients receiving go administration including toxic hepatitis, renal failure, deafness, skin rashes a various blood disorders.
It is therefore desirable to provide a method of treatment of musculoskelet and neural disorders which alleviates or ameliorates at least some of the difficulti associated with current treatment regimes.
Traditional Chinese remedies for the treatment of soft tissue injuries such sprains and swellings, particularly of the ankles, include the packing of raw sa extracted from seawater around a painful or swollen joint. The application of t salt reduces the pain and swelling in many cases.
Further, acupuncturists postulate that there are three dimensional ribbon-li structures called meridians which are embedded in the body and join t acupuncture points. These meridians are postulated to be present in all mammal It is postulated further that there is a flow of energy, possibly electromagneti energy, flowing through these meridians and if, for any reason, this flow of energ is disrupted, disease will occur. By re-establishing the energy flow, the pain an inflammation which are often associated with neural and musculoskeletal injuri or disorders, and attributable to a disruption of the flow of energy through t meridians, can be reduced and thus aid in the eventual healing process. Description of Prior Art
My earlier International Patent Application No. PCT/AU93/00384 disclos an invention which involves the external application of caesium chloride i conjunction with other compounds which produce a synergistic effect in treating wide variety of disorders in a patient, and the use of caesium chloride, either b itself or in conjunction with other compounds, in preparations for internal administration to a patient.
It has now been discovered that preparations containing rubidium ions, particularly but not exclusively in the form of rubidium chloride, can also be used effectively to treat musculoskeletal, neural and respiratory disorders, including those that are able to be treated with caesium chloride as described in my earlier patent application.
Various therapeutic uses of preparations containing rubidium ions have been previously proposed. A.K. Brewer, in an article entitled "The High pH Therapy for Cancer Tests on Mice and Humans" (Pharmacology Biochemistry & Behaviour,
Vol. 21, Suppl. 1, pp. 1-5 1984), has disclosed that potassium, rubidium and especially caesium can be effective when administered internally to treat cancer.
International Patent Application No. WO 94/11010 discloses that compositions of oak bark extract and synthetic mixtures containing potassium ions, zinc ions, calcium ions, rubidium ions and sulphur are useful in the treatment of skin cancer and other skin disorders. Australian Patent Application No. AU-B-20464 discloses a basic multiele ental composition comprising a combination of several elements, including rubidium, and having useful therapeutic, dermatocosmetic and dietetic properties. However, none of these prior- documents discloses the use of rubidium ions per se as a therapeutically active ingredient to treat musculoskeletal, neural or respiratory disorders.
Summary of the Invention
According to a one aspect of the present invention, there is provided a method of relieving pain in a patient suffering from a musculoskeletal, neural or respiratory disorder which method comprises administering to said patient a preparation wherein the therapeutically active ingredient is rubidium ions.
Preferably, the rubidium ions are in the form of rubidium chloride, RbCl.
It has been found that the external application of rubidium chloride reduces pain levels and swelling in swollen joints and has similar effects in the treatment of muscular disorders such as myositis.
The preparation containing rubidium chloride as the therapeutically active ingredient may be applied topically in the form of a gauze or other absorb medium which has been impregnated with an aqueous solution containing rubidiu chloride. The absorbent material may comprise any gauze or tissue, such as musl tissue or self-adhesive tissue paper, but may conveniently comprise a microporo synthetic fabric material such as material sold by Minnesota Mining a Manufacturing Company under the Trade Mark "MICROPORE". The impregnat material is left to dry preferably at room temperature before being cut or otherwi severed into conveniently sized portions which may be attached to the appropria part of the patient and secured in any convenient conventional manner. According to another aspect of the invention there is provided a topic preparation for use in a method of treating musculoskeletal. neural or respirato disorders in a patient wherein the preparation comprises an absorbent materi impregnated with a therapeutically effective amount of rubidium ions, preferab in the form of rubidium chloride. The rubidium chloride may be present in the absorbent material in a quanti of between about 0.01 mg/cm2 to about 1.0 mg/cm2, and preferably in a quanti of between about 0.1 mg/cm2 to about 0.5 mg/cm2. Brief Description of the Drawing
Fig. 1 illustrates a representative embodiment of the invention, a schemat section through a plastic strip having microporous material impregnated wi rubidium chloride on both sides. Description of the Preferred Embodiments Example 1
(1) One strip (A) of a self-adhesive microporous fabric material such "MICROPORE" is applied on each side of a layer of plastic (B), hence t plastic layer (B) is sandwiched between the two layers (A) of t microporous material. The strip-like product then formed into a roll.
(2) The strip-like product is then immersed in an aqueous solution of rubidiu chloride containing from about 0.1% to about 4%, preferably 2%, rubidium chloride for about 8-12 hours, after which it is taken out of th solution and dried. (3) The strip-like product can then be cut into patches of different sizes and the layers (A) of impregnated microporous material peeled off either side of the plastic strip (B) as required for application onto the skin of a patient. AMOUNT OF RUBIDIUM CHLORIDE IN PATCHES OF THE STRIP 40 g of RbCl dissolved in two (2) litres of water can produce 20 rolls of a strip 7.5 cm wide and 9 m long. The total area of the strip is therefore 135000 cm2 and contains 40 g of RbCl. Thus each cm2 of the strip contains approximately 0.30 mg of RbCl.
Experiments and clinical observations have indicated that following the application of a microporous strip impregnated with rubidium chloride, test patients suffering from skeletal muscular pain caused by injuries, arthritis or other types of inflammation have experienced pain relief in a short period of time. The following are examples of clinical observations of the effectiveness of the preparation:
(1) A strip of absorbent material manufactured in the manner above was applied to the ball of the foot of a person who had been suffering from severe pain in the ball of the foot for two weeks. The patient found he could walk without much trouble within thirty minutes, and experienced no more pain after three days of treatment.
(2) A woman suffering from chronic back pain suffered many sleepless nights and had found no effective commercially available medication. After two strips of absorbent material impregnated with rubidium ions were applied to her back, she had her first good nights sleep for many years.
(3) A child had fallen and hurt his knee. The knee was swollen and painful, but an X-ray showed no fracture. One strip of absorbent material impregnated with rubidium ions was applied on each side of the knee. Two days later, all the pain and swelling had gone.
The concentration of rubidium chloride in the solution in which the absorbent material is impregnated may be as high as 50%, although it is believed there is not a great increase in the effectiveness when compared with a strip of absorbent material manufactured as described with reference to the example above.
Conversely, concentrations as low as 0.01% RbCl per litre of water have been shown to be effective although the time taken to achieve the desired reducti in pain and swelling levels is increased.
It will, however, be appreciated that the method of the present invention m be performed using different forms of preparations containing rubidium ions external application to a patient. For instance, the method of the present inventi in its broadest ambit includes the external application to a patient of therapeutical effective amounts of rubidium ions contained in creams, gels, pastes, lotions a sprays or the like, and even bath salts containing rubidium ions which may added to baths, spa baths, mud baths etc. to provide a therapeutically effecti amount of rubidium ions in the bath. It is also contemplated that, within the sco of the present invention, herbs or plants may be grown in rubidium enriched fertilized soils or hydroponic solutions, with the plants being used to ma preparations to be fed or administered internally or externally to a patie Similarly, rubidium enriched clays containing therapeutically effective amounts rubidium ions may be applied externally to a patient.
There is also provided, in accordance with a further aspect of the inventio a topical preparation for external application to a patient wherein the preparati comprises a cream, gel, paste, lotion, spray or the like containing a therapeutical effective amount or rubidium ions, preferably in the form of rubidium chloride. The rubidium chloride may be incorporated into a cream base conventional means known in the art. The rubidium chloride may be present in t preparation in an amount falling substantially within the range from about 0.1% about 50% by weight. Preferably, the rubidium chloride is present in the cream a quantity of between about 0.1% and about 4% of the total weight of t preparation.
An embodiment of this aspect of the invention will now be described in t following example. Example 2
300 g of rubidium chloride (RbCl) is mixed with 15 kg of an aqueous crea base, and then bottled in 50 ml jars. Content of RbCl in the cream
300 g RbCl in 15 kg of cream = 20 g RbCl in 1 kg of cream
20 mg RbCl in 1 g of cream (2%). The cream may be applied by massaging gently into the affected areas.
Suggested therapeutic amounts of rubidium chloride for external application to a patient are from about 0.001 mg to about 0.04 mg per cm2 of the effected area of the patient. For example, 10 mg of cream containing about 2% of rubidium chloride may be applied over an area of skin of 10 cm2 thereby administering approximately 0.02 mg of RbCl per cm2 of skin.
Treatment with cream containing rubidium chloride can provide relief from arthritic pain in a short period of time. Preparations containing rubidium chloride have also been shown to provide beneficial effects when used in conjunction with orthodox methods of treatment, for example, physiotherapy or acupuncture. Apart from the treatment of musculoskeletal disorders including rheumatic or arthritic disorders, the external application of preparations containing rubidium ions to patients having painful varicose veins, and neural disorders such as, migraines or other severe headaches, toothache, ear ache, period pains and stomach pains, has been demonstrated to provide significant relief in pain levels experienced by the patient.
A further beneficial application of preparations containing rubidium ions, preferably rubidium chloride, whether alone or in conjunction with other compounds, is the application of the preparation internally or externally to relieve coughing, a blocked or runny nose, or other symptoms in a patient suffering from a respiratory disorder.
Thus, according to another broad aspect of the invention there is provided a method of treating disorders of the respiratory system of a patient, which method comprises administering to said patient a preparation containing rubidium ions, preferably rubidium chloride. This method of treatment finds particular application in the relief of coughing and chest congestion, relief from croup attack in children, as well as relief of the symptoms of hayfever. It will, however, be appreciated that the inventi is not limited thereto and the treatment of patients having other symptoms respiratory disorders such as blocked or runny noses or other symptoms of asthm common colds and influenza falls within the ambit of the present invention. In treating respiratory disorders the rubidium ions may be administered eith externally or internally to the patient.
The rubidium ions may be administered externally by applying a topic preparation, for instance a cream, paste, lotion, spray or the like containi rubidium chloride, to the chest, throat, nasal area or other part of the body of t patient. The present invention therefore includes within its ambit a topic preparation for use in the treatment of respiratory disorders, wherein the preparati contains a therapeutically effective amount of rubidium ions preferably in the for of rubidium chloride.
The preparation is preferably applied topically in the form of a crea containing rubidium chloride.
The rubidium chloride may be incorporated into a cream base b conventional means known in the art. The cream preparation described above f use in the treatment of musculoskeletal and neural disorders has been found to equally effective in relieving coughing and congestion in patients suffering fro respirator) disorders. As described above, the rubidium chloride is preferabl present in the cream in a quantity of between about 0.1% and about 4% of the tot weight of the preparation.
The cream may be applied by massaging gently into the affected area, suc as the chest or throat and has been shown to provide positive suppression coughing within minutes after application. The cream can also provide relief most symptoms of hayfever by applying it around the nasal area.
It has also been found that rubidium ions, preferably in the form of rubidiu chloride, administered internally to a patient also have beneficial effects i suppressing or relieving any type of cough, as well as relieving most symptoms hayfever. The rubidium ions may be administered internally in any convenie form, for instance, an aqueous solution of rubidium chloride could be used in nebulizer, in an aerosol inhaler, in a nasal spray, as a mouth wash or administered with a dropper. Additionally, rubidium chloride could be added to a liquid or syrup to produce a cough mixture. Thus, the present invention also includes within its ambit a preparation for internal administration to a patient for treating coughs, respiratory disorders or hayfever, wherein the preparation comprises a carrier and, as the therapeutically active ingredient, rubidium ions.
In a preferred embodiment of this aspect of the invention the preparation comprises an aqueous solution of rubidium chloride. The aqueous solution may contain from about 0.01% to about 50% of rubidium chloride and preferably contains between about 0.2% and about 4% of rubidium chloride. Such a solution is preferably placed within a nebulizer or aerosol inhaler for administration to a patient who then can inhale a dose of rubidium chloride from about 0.08 mg to about 1.6 mg from the nebulizer or aerosol inhaler as described with reference to the following example. Example 3
An amount of rubidium chloride (RbCl) is dissolved in distilled water to produce an aqueous solution containing about 2% rubidium chloride, 2 ml of which is then placed in a nembulizer or aerosol inhaler.
2 ml of a 1% solution contains 0.04 g RbCl. 2 ml is a sufficient quantity for about 50 inhalations or "puffs". Thus each puff or inhalation from the nembulizer or inhaler contains 0.8 mg of RbCl.
Inhalations containing rubidium chloride have been found to suppress coughs within a matter of a few minutes, and such inhalations have also been found to suppress and relieve symptoms of hayfever. No significantly adverse effects have been noticed in patients that have repeatedly inhaled doses of rubidium chloride from a nebulizer or aerosol inhaler.
Rubidium chloride appears to be a selective blocker for local nerve endings.
In this case, it blocks the transmission of a signal that would result in a cough. It also appears to have an anti-histamine like property, since it can suppress the symptoms of hayfever, although the actual mechanism is not clear. It also has a bronchodilatory effect, which is more powerful than the most commonly used bronchial dilator SALBUTAMOL (VENTOLIN).
Coughs due to colds cause extreme distress to typical northern hemisphe wintertime residents. Any treatment that would reduce the drain of energy a health in the course of the cold would certainly help in recovery from the comm cold.
Croup attack in children can be a terrifying experience to a child too you to be able to understand the explanations made by adults. The incessant nature this complaint can easily cause more pain and suffering to the parents than to t child. However, cream containing rubidium chloride can rapidly bring relief t both the child and indirectly to the parents.
It is desirable to state that many different kinds of cough can be suppresse because it is postulated that the rubidium chloride is selectively blocking the nerve rather than responding to a specific affliction that produces that cough. Here th intrinsic healing capabilities of the body are potentiated by removal of th antagonism caused by coughing.
From the above description, it will be appreciated that the methods an preparations of the present invention is effective in relieving pain caused b musculoskeletal and neural disorders, in suppressing coughs and in treating o relieving pain in other respiratory disorders. Preparations containing rubidium ion for instance in the form of rubidium chloride have also been found to be effectiv in treating inflammation of epithelial tissue such as lining of respiratory system an gastrointestinal system.
The present invention has also identified that preparations including rubidiu ions, preferably rubidium chloride, can be administered internally for variou therapeutic treatments, particularly for treating respiratory and bronchial disorders and also as a local anaesthetic. It will also be appreciated that variou modifications and alterations may be made to the methods and preparation described above without departing from the scope and spirit of the presen invention.

Claims (47)

CLAIMS:
1. A method of treating or relieving pain in a patient suffering from a musculoskeletal, neural or respiratory disorder, which method comprises administering to said patient a preparation in which the therapeutically active ingredient is rubidium ions.
2. A method according to claim 1 wherein the composition is administered externally to the patient.
3. A method according to claim 1 or claim 2 wherein the rubidium ions are present in the form of rubidium chloride.
4. A method according to claim 2 wherein the composition is administered topically in the form of an absorbent material impregnated with an aqueous solution containing rubidium ions.
5. A method according to claim 4 wherein an absorbent material containing an amount of rubidium chloride falling substantially within the range from about 0.01 to about 1.0 mg cm2 is applied to the patient.
6. A method according to claim 4 wherein an absorbent material containing an amount of rubidium chloride falling substantially within the range from about 0.1 to about 0.5 mg/cm2 is applied externally to the patient.
7. A method according to claim 4 wherein an absorbent material containing approximately 0.3 mg/cm2 is applied externally to the patient.
8. A method according to claim 2 wherein the preparation is administered topically in the form of a cream, gel, paste, lotion, spray or the like containing a therapeutically effective amount of rubidium ions.
9. A method according to claim 8 wherein the rubidium ions are present in the form of rubidium chloride.
10. A method according to claim 9 wherein the preparation contains an amount of rubidium chloride falling substantially within the range from about 0.01% to about 50% by weight.
11. A method according to claim 10 wherein the preparation contains an amount of rubidium chloride falling substantially within the range from about 0.1% to about 4% by weight.
12. A method according to claim 10 wherein the preparation contains an amou of approximately 2% by weight of rubidium chloride.
13. A method according to claim 2 wherein the preparation is administered the patient by applying doses containing an amount of rubidium chloride falli substantially within the range from about 0.0001 to about 0.04 mg per cm2 to t affected area of the patient.
14. A method according to claim 2 wherein the preparation is administered the form of a bath salt containing rubidium ions.
15. A method of treating or relieving pain in a patient suffering from respiratory disorder wherein a preparation containing rubidium ions as therapeutically active ingredient is administered internally to the patient.
16. A method according to claim 15 wherein the preparation is administered the patient in the form of a liquid, syrup or aqueous solution containing rubidiu ions.
17. A method according to claim 16 wherein the preparation is administered the patient in the form of a nebulizer, aerosol inhaler or spray containing aqueous solution of rubidium ions.
18. A method according to any one of claims 15 to 17 wherein the rubidiu ions are present in the form of rubidium chloride.
19. A method according to claim 18 wherein an aqueous solution containing a amount of rubidium chloride falling substantially within the range from abo
0.01% to about 50% is administered to the patient.
20. A method according to claim 19 wherein an aqueous solution containing a amount of rubidium chloride falling substantially within the range from about 0.2 to about 4% is administered to the patient.
21. A method according to claim 16 wherein an aqueous solution containin approximately 2% of rubidium chloride is administered to the patient.
22. A method according to claim 16 wherein the preparation is administered t the patient in doses containing an amount of rubidium chloride falling substantiall within 1.6 mg the range from about 0.08 mg to about 1.6 mg.
23. A method according to claim 16 wherein the preparation is administered t the patient in doses containing an amount of rubidium chloride of approximately 0.8 mg.
24. A preparation for the treatment or relief of pain in a patient suffering from a musculoskeletal, neural or respiratory disorder comprising a carrier for external administration to a patient and, as the sole therapeutically active ingredient, rubidium ions.
25. A preparation according to claim 24 wherein the rubidium ions are present in the form of rubidium chloride.
26. A preparation according to claim 24 comprising an absorbent material impregnated with a therapeutically effective amount of rubidium ions.
27. A preparation according to claim 24 wherein the absorbent material is impregnated with a solution containing rubidium chloride.
28. A preparation according to claim 27 wherein the rubidium chloride is present in the absorbent material in an amount falling substantially within the range from about 0.01 mg/cm2 to about 1.0 mg/cm2 of the absorbent material.
29. A preparation according to claim 27 wherein the rubidium chloride is present in the absorbent material in an amount falling substantially within the range from about 0.1 mg/cm2 to about 0.5 mg/cm2 of the absorbent material.
30. A preparation according to claim 29 wherein the rubidium chloride is present in the absorbent material in an amount of approximately 0.3 mg/cm2 of the absorbent material.
31. A preparation according to claim 24 comprising a cream, gel, paste, lotion, spray or the like containing a therapeutically effective amount of rubidium ions.
32. A preparation according to claim 31 wherein the rubidium ions are present in the form of rubidium chloride.
33. A preparation according to claim 32 wherein the preparation contains an amount of rubidium chloride falling substantially within the range from about 0.01% to about 50% by weight.
34. A preparation according to claim 33 wherein the preparation contains an amount of rubidium chloride falling substantially within the range from about 0.1 % to about 4% by weight.
35. A preparation according to claim 34 wherein the preparation contai rubidium chloride in an amount of approximately 2% by weight.
36. A preparation for the treatment or relief of pain in a patient suffering fro respiratory disorder comprising a carrier for internal administration to a patient an as the therapeutically active ingredient, rubidium ions.
37. A preparation according to claim 36 comprising an aqueous solution rubidium chloride.
38. A preparation according to claim 37 wherein the aqueous solution contai an amount of rubidium chloride falling substantially within the range from abo 0.01% to about 50%.
39. A preparation according to claim 38 wherein the aqueous solution contain an amount of rubidium chloride falling substantially within the range from abo 0.2% to about 4%.
40. A preparation according to claim 39 wherein the aqueous solution contain approximately 2% of rubidium chloride.
41. A method of making a therapeutic preparation comprising the steps o immersing an absorbent material with an aqueous solution containing rubidium ion so as to impregnate the absorbent material with a therapeutic amount of rubidiu ions, and allowing the absorbent material to dry.
42. A method according to claim 41 wherein a layer of absorbent fabric materia is applied on one side of a layer of plastics backing material to form a strip whic is immersed in the aqueous solution so as to impregnate the layer of absorben material with a therapeutic amount of rubidium ions.
43. A method according to claim 41 wherein two layers of absorbent fabri material are applied to opposite sides of a layer of plastics backing material to for a strip which is immersed in the aqueous solution so that both layers of absorben fabric material on opposite sides of the backing material are impregnated with therapeutic amount of rubidium ions.
44. A method according to any one of claims 41 to 43 wherein the absorben material is immersed in an aqueous solution containing rubidium chloride.
45. A method according to claim 44 wherein the aqueous solution contains concentration of rubidium chloride falling substantially within the range from 1 g/1 to 40 g/1.
46. A method according to claim 45 wherein the aqueous solution contains a concentration of about 20 g/1 of rubidium chloride. 47. A method according to any one of claims 41 to 46 wherein the absorbent material comprises any one of the following: a gauze, muslin tissue, self-adhesive tissue paper or a microporous synthetic fabric material.
45. A method according to claim 44 wherein the aqueous solution contains a concentration of rubidium chloride falling substantially within the range from 1 g/1 to 40 g/1.
46. A method according to claim 45 wherein the aqueous solution contains a concentration of about 20 g/1 of rubidium chloride.
47. A method according to any one of claims 41 to 46 wherein the absorbent material comprises any one of the following: a gauze, muslin tissue, self-adhesive tissue paper or a microporous synthetic fabric material.
AU46149/96A 1995-02-10 1996-02-09 Therapeutic methods and preparations using rubidium ions Ceased AU696938C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU46149/96A AU696938C (en) 1995-02-10 1996-02-09 Therapeutic methods and preparations using rubidium ions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPN1048 1995-02-10
AUPN1048A AUPN104895A0 (en) 1995-02-10 1995-02-10 Methods of and preparations for the treatment of ailments and disorders
AU46149/96A AU696938C (en) 1995-02-10 1996-02-09 Therapeutic methods and preparations using rubidium ions
PCT/AU1996/000067 WO1996024363A1 (en) 1995-02-10 1996-02-09 Therapeutic methods and preparations using rubidium ions

Publications (3)

Publication Number Publication Date
AU4614996A AU4614996A (en) 1996-08-27
AU696938B2 AU696938B2 (en) 1998-09-24
AU696938C true AU696938C (en) 1999-07-22

Family

ID=

Similar Documents

Publication Publication Date Title
CN108853312B (en) Polycinnamic alcohol external gel and preparation method thereof
US5589480A (en) Topical application of opioid analgesic drugs such as morphine
Finley Ellingwood American materia medica, therapeutics and pharmacognosy
CN109364226A (en) A kind of active relaxing muscles and tendons of moisturizing is releived the ancient method plants essential oil ached and preparation method
US6011061A (en) Therapeutic methods and preparations using rubidium ions
US5945119A (en) Therapeutic preparations containing caesium ions
CN103656025B (en) A kind of medical liquor for treating injury
AU696938C (en) Therapeutic methods and preparations using rubidium ions
CN102743587A (en) External application wound repair liquid
AU674151B2 (en) Therapeutic methods using caesium ions
RU2718061C1 (en) Compositions and methods of treating paranasal sinus and parasitic nasal mucosa diseases with nicotinic acetylcholine receptor agonists
CN105031156A (en) Plaster for treating traumatic injuries
CN110585379A (en) External application medicine for treating dermatitis
CN107648437A (en) A kind of Chinese medicine for treating rhinitis cream
CN101406579A (en) Novel use of pinellia
CN116350709A (en) Hydrogel patch for treating children cough due to lung heat and preparation method thereof
CN113350410A (en) Traditional Chinese medicine composition for treating bronchiectasis, preparation method and application thereof
JPS6229529A (en) Manufacture of medicine for disease
Dharmananda Relationship of Borneol, Artemesia and Moxa
CN110433227A (en) A kind of External-applicationtraditional traditional Chinese medicinal of blood stasis dispersing and deswelling
Files Common Name: Bloodroot| Scientific Name: Sanguinaria Canadensis
CN117599148A (en) Foot-use Chinese and western medicine combination medicine and preparation method thereof
CN112773822A (en) Pharmaceutical formulation for wound healing
KR100631293B1 (en) Nose Poultice For Curing Colds
CN1250660A (en) Liquid medicine for treating wound and pain